Wendy Becker Buys 536 Shares of GSK plc (LON:GSK) Stock

GSK plc (LON:GSK) insider Wendy Becker acquired 536 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The shares were bought at an average cost of GBX 1,515 ($19.56) per share, for a total transaction of £8,120.40 ($10,484.70).

GSK Price Performance

Shares of LON GSK opened at GBX 1,509 ($19.48) on Friday. The firm has a market capitalization of £61.23 billion, a P/E ratio of 24.38, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The stock’s 50-day simple moving average is GBX 1,441.42 and its two-hundred day simple moving average is GBX 1,437.45. GSK plc has a twelve month low of GBX 1,282.50 ($16.56) and a twelve month high of GBX 1,823.50 ($23.54).

GSK (LON:GSK) last announced its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities analysts anticipate that GSK plc will post 175.980975 EPS for the current fiscal year.

Analyst Ratings Changes

GSK has been the topic of a number of recent research reports. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank dropped their price objective on GSK from GBX 1,820 ($23.50) to GBX 1,600 ($20.66) and set a “buy” rating on the stock in a report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($23.32).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.